Conagen inc

Biotech · Private

Microbial fermentation platform for anthocyanin production using metabolically engineered microorganisms

Grants
$225K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
40
16 granted · 24 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · STTR Phase I: Recombinant production of anthocyanins in a GRAS microorganism$225,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2194ADVERTENT BIOTHERAPEUTICS, INC.——
2195Avometric——
2196OVATION SCIENCE INC.—$150K
2197Conagen inc——
2198SPHEREBIO, INC.——
2199Egaceutical Corp—$9K
2200ME THERAPEUTICS HOLDINGS INC.—$3K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 16 granted of 40

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.